{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:54:51Z","timestamp":1788184491643,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cardiovascular safety of anticancer drug immune checkpoint inhibitors (ICIs) used in patients with malignant tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four clinical research databases that have been completed since their establishment were searched, and the odds ratios and 95% confidence intervals of each indicator were statistically calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>62 randomized controlled trial and controlled trials were included. In single drug treatment ICIs group, the overall risk of cardio cerebral Vascular disease at all levels was higher than that in the placebo\/chemotherapy group. Especially in all grades of Myocarditis and above grade 3 compared with normal controls, except for pericardial lesions, other indicators have no obvious side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Single drug use of an anti-tumor ICIs may increase cardiovascular side effects risk in cancer patients, so we need to strengthen monitoring, identification and management, and timely intervention to manage ICI induced adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1394123","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:21:53Z","timestamp":1719188513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Xi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition\u2014novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/medicina60020224","article-title":"Perimyocarditis associated with immune checkpoint inhibitors: A case report and review of the literature","volume":"60","author":"Shalata","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review","author":"Shalata","year":"2021","journal-title":"Cancers(Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1965988","article-title":"Gastrointestinal and cardiovascular adverse events associated with NSAIDs","volume":"21","author":"Domper Arnal","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14546","article-title":"Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports","volume":"87","author":"Goldman","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00300-y","article-title":"Serious cardiovascular adverse events associated with hydroxychloroquine\/chloroquine alone or with azithromycin in patients with COVID-19: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"9","author":"Zhao","year":"2022","journal-title":"Drugs-Real World Outcomes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.0640","article-title":"Cardiovascular adverse events with intravitreal anti\u2013vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials","volume":"139","author":"Ntjam","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01457-w","article-title":"An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19","volume":"44","author":"Luo","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000519687","article-title":"Evaluation of cardiac adverse events associated with carfilzomib using a Japanese real-world database","volume":"100","author":"Nakao","year":"2022","journal-title":"Oncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor\u2013associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.08.004","article-title":"Immune cell infiltration landscapes in pediatric acute myocarditis analyzed by CIBERSORT","volume":"77","author":"Kawada","year":"2021","journal-title":"J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001042","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34169","article-title":"Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis","volume":"151","author":"Cau","year":"2022","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Modern Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor\u2013Associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.08.003","article-title":"Acute ischemia alters human pericardial fluid immune cell composition","volume":"6","author":"Fatehi Hassanabad","year":"2021","journal-title":"Basic to Trans Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2020.04.006","article-title":"The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment","volume":"31","author":"Lopalco","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/medicina59111946","article-title":"Tolerated re-challenge of immunotherapy in a patient with ICI associated myocarditis: A case report and literature review","volume":"59","author":"Shalata","year":"2023","journal-title":"Medicina(Kaunas)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13707","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"47","author":"Wang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.15586\/aei.v49i3.99","article-title":"Acute pericarditis: A peculiar manifestation of common variable immune deficiency","volume":"49","author":"Ramzi","year":"2021","journal-title":"Allergologia immunopathologia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2020.12.200432","article-title":"Pericarditis in contemporary therapeutic clinic: nosological spectrum, approaches to diagnosis and treatment","volume":"92","author":"Blagova","year":"2020","journal-title":"Terapevticheskii arkhiv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1394123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:21:56Z","timestamp":1719188516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1394123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2024.1394123"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1394123","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"article-number":"1394123"}}